Johnson & Johnson (NYSE:JNJ) Shares Sold by BRYN MAWR TRUST Co

BRYN MAWR TRUST Co lowered its holdings in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 3.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 266,892 shares of the company’s stock after selling 10,336 shares during the period. Johnson & Johnson makes up 2.2% of BRYN MAWR TRUST Co’s holdings, making the stock its 8th largest position. BRYN MAWR TRUST Co’s holdings in Johnson & Johnson were worth $47,376,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. RE Dickinson Investment Advisors LLC raised its stake in Johnson & Johnson by 163.3% during the 1st quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock valued at $28,000 after acquiring an additional 98 shares in the last quarter. Advanced Research Investment Solutions LLC raised its stake in shares of Johnson & Johnson by 200.0% in the 1st quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock worth $32,000 after buying an additional 120 shares in the last quarter. Morton Brown Family Wealth LLC raised its stake in shares of Johnson & Johnson by 78.0% in the 2nd quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock worth $32,000 after buying an additional 78 shares in the last quarter. Professional Financial Advisors LLC raised its stake in shares of Johnson & Johnson by 47.9% in the 1st quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock worth $37,000 after buying an additional 68 shares in the last quarter. Finally, Goodman Advisory Group LLC bought a new stake in shares of Johnson & Johnson in the 2nd quarter worth $39,000. Institutional investors own 68.59% of the company’s stock.

Insider Buying and Selling

In related news, VP Peter Fasolo sold 22,864 shares of the business’s stock in a transaction dated Wednesday, October 19th. The stock was sold at an average price of $164.50, for a total transaction of $3,761,128.00. Following the completion of the transaction, the vice president now owns 114,676 shares of the company’s stock, valued at approximately $18,864,202. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Johnson & Johnson news, insider William Hait sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, October 24th. The stock was sold at an average price of $171.55, for a total value of $2,573,250.00. Following the completion of the transaction, the insider now owns 80,236 shares of the company’s stock, valued at approximately $13,764,485.80. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Peter Fasolo sold 22,864 shares of the company’s stock in a transaction that occurred on Wednesday, October 19th. The shares were sold at an average price of $164.50, for a total value of $3,761,128.00. Following the completion of the transaction, the vice president now directly owns 114,676 shares of the company’s stock, valued at approximately $18,864,202. The disclosure for this sale can be found here. In the last 90 days, insiders sold 212,646 shares of company stock valued at $36,791,022. Insiders own 0.35% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on JNJ. Raymond James dropped their price objective on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 19th. Sanford C. Bernstein dropped their price objective on Johnson & Johnson from $194.00 to $190.00 in a research note on Wednesday, October 19th. Morgan Stanley dropped their price objective on Johnson & Johnson from $174.00 to $170.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 19th. Citigroup cut their target price on Johnson & Johnson from $201.00 to $198.00 in a research report on Wednesday, October 5th. Finally, Atlantic Securities cut their target price on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 19th. Seven research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $181.33.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $177.01 on Thursday. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $186.69. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37. The company has a market capitalization of $462.79 billion, a price-to-earnings ratio of 24.65, a P/E/G ratio of 3.49 and a beta of 0.57. The stock’s fifty day simple moving average is $168.35 and its 200-day simple moving average is $171.28.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its earnings results on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, beating analysts’ consensus estimates of $2.49 by $0.06. The firm had revenue of $23.79 billion for the quarter, compared to the consensus estimate of $23.44 billion. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The business’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.60 earnings per share. On average, sell-side analysts predict that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.

Johnson & Johnson announced that its board has authorized a stock repurchase plan on Wednesday, September 14th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the company to purchase up to 1.2% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s management believes its stock is undervalued.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 6th. Investors of record on Tuesday, November 22nd will be given a dividend of $1.13 per share. The ex-dividend date of this dividend is Monday, November 21st. This represents a $4.52 annualized dividend and a dividend yield of 2.55%. Johnson & Johnson’s dividend payout ratio is presently 62.95%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.